Topics

Bluebird says gene therapy application delayed again, citing disagreement with FDA

07:40 EDT 26 Mar 2020 | BioPharmaDive

The biotech now expects to complete its FDA submission for LentiGlobin by mid next year, roughly a year past when it first expected to finish filing its application.

Original Article: Bluebird says gene therapy application delayed again, citing disagreement with FDA

NEXT ARTICLE

More From BioPortfolio on "Bluebird says gene therapy application delayed again, citing disagreement with FDA"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...